Recent developments on treatment strategies and the prognosis of dermatomyositis: a review
Dermatomyositis is an autoimmune disease affecting both skin and muscle. Steroids are the first line treatment. However, no consensus regarding dosing, length of treatment, tapering speed, or when to add which immunosuppressant in case of steroid resistance, has been reached, as randomized-controlle...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2017.1403549 |
| _version_ | 1797683740246278144 |
|---|---|
| author | Verena Isak Joseph L. Jorizzo |
| author_facet | Verena Isak Joseph L. Jorizzo |
| author_sort | Verena Isak |
| collection | DOAJ |
| description | Dermatomyositis is an autoimmune disease affecting both skin and muscle. Steroids are the first line treatment. However, no consensus regarding dosing, length of treatment, tapering speed, or when to add which immunosuppressant in case of steroid resistance, has been reached, as randomized-controlled trials are scarce. Especially data on long-term treatment is lacking in order to decide on the most effective treatment for long-term remission. Empiric evidence suggests that with an initially aggressive treatment with oral steroids followed by a slow taper, during which disease activity is adequately controlled, patients can be off therapy within typically 24–48 months, and remain disease-free without medication for over 20 years. Biologics such as rituximab have shown good results in the treatment of refractory DM. New, targeted therapies have been reported to improve DM in single cases or case series, but have to be evaluated for efficacy in randomized controlled trials. |
| first_indexed | 2024-03-12T00:19:07Z |
| format | Article |
| id | doaj.art-5e12c77820e144588fa37020d5db7302 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:19:07Z |
| publishDate | 2018-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5e12c77820e144588fa37020d5db73022023-09-15T14:08:31ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-07-0129545045910.1080/09546634.2017.14035491403549Recent developments on treatment strategies and the prognosis of dermatomyositis: a reviewVerena Isak0Joseph L. Jorizzo1Winston SalemWinston SalemDermatomyositis is an autoimmune disease affecting both skin and muscle. Steroids are the first line treatment. However, no consensus regarding dosing, length of treatment, tapering speed, or when to add which immunosuppressant in case of steroid resistance, has been reached, as randomized-controlled trials are scarce. Especially data on long-term treatment is lacking in order to decide on the most effective treatment for long-term remission. Empiric evidence suggests that with an initially aggressive treatment with oral steroids followed by a slow taper, during which disease activity is adequately controlled, patients can be off therapy within typically 24–48 months, and remain disease-free without medication for over 20 years. Biologics such as rituximab have shown good results in the treatment of refractory DM. New, targeted therapies have been reported to improve DM in single cases or case series, but have to be evaluated for efficacy in randomized controlled trials.http://dx.doi.org/10.1080/09546634.2017.1403549dermatomyositisinflammatory myopathysystemic steroidsimmunosuppressants |
| spellingShingle | Verena Isak Joseph L. Jorizzo Recent developments on treatment strategies and the prognosis of dermatomyositis: a review Journal of Dermatological Treatment dermatomyositis inflammatory myopathy systemic steroids immunosuppressants |
| title | Recent developments on treatment strategies and the prognosis of dermatomyositis: a review |
| title_full | Recent developments on treatment strategies and the prognosis of dermatomyositis: a review |
| title_fullStr | Recent developments on treatment strategies and the prognosis of dermatomyositis: a review |
| title_full_unstemmed | Recent developments on treatment strategies and the prognosis of dermatomyositis: a review |
| title_short | Recent developments on treatment strategies and the prognosis of dermatomyositis: a review |
| title_sort | recent developments on treatment strategies and the prognosis of dermatomyositis a review |
| topic | dermatomyositis inflammatory myopathy systemic steroids immunosuppressants |
| url | http://dx.doi.org/10.1080/09546634.2017.1403549 |
| work_keys_str_mv | AT verenaisak recentdevelopmentsontreatmentstrategiesandtheprognosisofdermatomyositisareview AT josephljorizzo recentdevelopmentsontreatmentstrategiesandtheprognosisofdermatomyositisareview |